- Home
- KPRX vs CSCI Comparison
KPRX vs CSCI Comparison
Compare KPRX & CSCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- CSCI
- Stock Information
- Founded
- KPRX 1998
- CSCI 1990
- Country
- KPRX United States
- CSCI Canada
- Employees
- KPRX N/A
- CSCI N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CSCI
- Sector
- KPRX Health Care
- CSCI
- Exchange
- KPRX Nasdaq
- CSCI NYSE
- Market Cap
- KPRX 8.3M
- CSCI 9.9M
- IPO Year
- KPRX N/A
- CSCI 1996
- Fundamental
- Price
- KPRX $3.12
- CSCI $3.38
- Analyst Decision
- KPRX Strong Buy
- CSCI
- Analyst Count
- KPRX 1
- CSCI 0
- Target Price
- KPRX $10.00
- CSCI N/A
- AVG Volume (30 Days)
- KPRX 11.2K
- CSCI 3.5K
- Earning Date
- KPRX 05-20-2025
- CSCI 05-20-2025
- Dividend Yield
- KPRX N/A
- CSCI N/A
- EPS Growth
- KPRX N/A
- CSCI N/A
- EPS
- KPRX 0.87
- CSCI N/A
- Revenue
- KPRX $16,020,000.00
- CSCI $9,587,000.00
- Revenue This Year
- KPRX N/A
- CSCI N/A
- Revenue Next Year
- KPRX N/A
- CSCI N/A
- P/E Ratio
- KPRX $3.68
- CSCI N/A
- Revenue Growth
- KPRX N/A
- CSCI 34.22
- 52 Week Low
- KPRX $2.51
- CSCI $1.96
- 52 Week High
- KPRX $5.55
- CSCI $11.10
- Technical
- Relative Strength Index (RSI)
- KPRX 50.24
- CSCI N/A
- Support Level
- KPRX $3.18
- CSCI N/A
- Resistance Level
- KPRX $3.48
- CSCI N/A
- Average True Range (ATR)
- KPRX 0.19
- CSCI 0.00
- MACD
- KPRX 0.02
- CSCI 0.00
- Stochastic Oscillator
- KPRX 45.39
- CSCI 0.00
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About CSCI COSCIENS BIOPHARMA INC
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology. The Company has two reportable and operating segments: Active ingredient and Biopharmaceutical.